Synchron said all six participants met the primary safety endpoint, with no device-related serious adverse event causing death or permanently increased disability during the first year. The company also reported no serious brain- or vascular-related adverse events. All devices were deployed at the intended target with motor-cortex coverage, and median deployment time was 20 minutes.
Motor-intent signals were consistently converted into digital actions on computers. The results were presented at the 2024 Congress of Neurological Surgeons. The public disclosure did not contain two-year follow-up and did not describe a completed pivotal trial. A six-person cohort also leaves long-term durability and broader-population risk unanswered.